{
  "docId": "019de074-0cc8-70d5-8924-3a1b552a09af",
  "docSlug": "77b0d3b8437e31981ed49d98afb5005f",
  "documentTitle": "OmniAb | Investor Conference Presentation Deck | 43 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 43,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "other",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide illustrates how two different platforms (OmniFlic and OmniClic) converge into a single bispecific IgG format.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de074-0cc8-70d5-8924-3a1b552a09af/13",
  "deckHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af",
  "deckJsonHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af.json",
  "deckAnchorHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.57,
        "x": 0.415,
        "y": 0.27
      },
      "kind": "callout",
      "text": "Bispecifics are a growing area of therapeutics (20% of mAbs in clinic) ~30% of new OmniAb programs seek to use OmniFlic or OmniClic",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e74bb31-9a37-4708-ab93-3c303fcbb171",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.18,
        "x": 0.8,
        "y": 0.65
      },
      "kind": "callout",
      "text": "Common light chain for OmniFlic and OmniClic allows interchangeability between the platforms",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca28db03-c7b7-4a09-b8d7-28e9cbe0ca62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.04,
        "y": 0.3
      },
      "kind": "image",
      "text": "OmniFlic and OmniClic platform diagrams showing light chain rearrangement and antibody structures",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a16aaa42-ef7f-4dd9-a30d-de2785d17049",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.3,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "The Evolution of Bispecifc Antibodies, Nimish Gera https://doi.org/10.1080/14712598.2022.2040987",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3646252-6b33-4fbc-bd0e-cb74ee7ee80b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "STANDARD IgG FORMAT TO DE-RISK DOWNSTREAM DEVELOPMENT",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "418138e0-10cc-4e7d-b8af-d7ddd1702c3e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Common Light Chain Platforms for Bispecific Antibodies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bffee64f-c5e3-44d7-9c5e-74d6c1c224de",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 7,
      "beatId": "3040f323-ee51-48d4-9506-f542b79a5e56",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-16 present OmniAb's platform and its capabilities.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d28165e9-330b-4b4c-9bd6-8826c981bf1a",
      "evidence": "Slides 6-16 imply that not using OmniAb's platform may lead to lower success rates for antibody medicines.",
      "position": 0,
      "objective": "Highlight the consequences of not adopting OmniAb's technology",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}